MatriSys closer to begin testing MSB-01 for Atopic Dermatitis, afer FDA’s positive feedback

MatriSys closer to begin testing MSB-01 for Atopic Dermatitis, afer FDA’s positive feedback

March 21, 2019 Off By Dino Mustafić

MatriSys Bioscience got positive feedback from the FDA on its planned initiation of clinical trials for MSB-01 under a U.S. IND for MatriSys’ lead microbiome-based candidate, MSB-01, for the treatment of Atopic Dermatitis (AD).

“The positive feedback received from the FDA is encouraging and paves the way for submission of an IND application to the FDA and a Phase 2 trial for Atopic Dermatitis,” said Mark S. Wilson, MatriSys Bioscience Chief Executive Officer.

MatriSys plans to conduct a Phase 2 clinical trial with 150 patients over a 12-week treatment period. The trial will include a randomized double-blind, placebo-controlled safety, tolerability, and efficacy study using MSB-01 to treat atopic dermatitis, it said in a statement.